MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer, and a service provider for image interpretation and management in oncology clinical trials, today announced that it has signed a €206K firm contract with one of its top 10 biopharmaceutical company client. The contract covers the implementation of an exploratory imaging biomarker, tumor volume, in a first-in-man phase I study on adult patients with advanced malignant solid tumors. Within the framework of the contract, Progression Free Survival (PFS) will be measured on patients enrolled with RECIST 1.1 1. This widely-used standard criterion for response evaluation in solid tumors is based on lesion axial diameter measurements. In parallel, MEDIAN will implement an exploratory imaging biomarker based on tumor volume that provides more accurate and earlier information regarding patient response to therapy.